Understanding how BCL10 mutations affect treatment resistance in a type of lymphoma
Official title: Overcoming Drug Resistance Driven by BCL10 Mutations in Diffuse Large B Cell Lymphoma
Funded at University of Miami School of Medicine · NIH-10894687 · Data updated 2026-11-12
This study is looking at how certain changes in a gene called BCL10 might make it harder for people with diffuse large B cell lymphoma to respond to standard treatments, with the goal of finding better ways to help those patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | August 1, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $53,974 |
| NIH project number | 5F30CA265106-04 |
| Project ID | NIH-10894687 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with diffuse large B cell lymphoma, particularly those with identified BCL10 mutations.
✕Less likely to help
Patients with DLBCL who do not have BCL10 mutations may not benefit directly from the findings of this research.
What this research studies
This research focuses on diffuse large B cell lymphoma (DLBCL), a common and aggressive form of cancer. It aims to investigate the role of BCL10 mutations in causing resistance to standard treatments, using advanced models to understand how these mutations contribute to cancer progression. By identifying the mechanisms behind this resistance, the research seeks to discover new therapeutic strategies that could improve outcomes for patients with these mutations.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with DLBCL who have BCL10 mutations, potentially improving their survival rates.
How similar studies have gone: Previous research has shown promising results in targeting mutations in cancer therapies, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Coughlin, Caroline Alice — University of Miami School of Medicine
- Study coordinator: Coughlin, Caroline Alice
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.